Emergence of In Silico in Health Policy & Regulatory Science

In this exclusive interactive session, we explore the latest developments across several critical strategic initiatives. We focus specifically on the proposed MDR revision, the Biotech Act, and the breakthrough pathways — all of which now explicitly reference in silico methodologies. Agenda & Objectives Given the strategic importance of this moment for our community, the session is structured in three parts:

1. Advocacy Milestones: we begin with a concise update on the long-standing advocacy efforts led by VPH members and partners, providing context for our current standing.

2. A Decisive Shift: we examine the significant evolution in how in silico medicine and digital technologies are being integrated into the EU’s regulatory and innovation frameworks.

3. Shaping the Future: the session concludes with a set of clear action items designed to influence the evolving policy landscape.

This meeting catalyses the sustained engagement required over the coming months.

Watch the full Briefing Session recording – now publicly available after an initial period reserved for VPH members.

VPH members benefit from exclusive early access to time-sensitive content and community insights. If you’d like to stay ahead and access future materials as soon as they are released, we invite you to explore our membership plans and their benefits. Already a member? Make sure your membership is renewed for 2026 by logging into your personal account. For any clarifications you might need, please visit our FAQ  or contact us.

WATCH HERE ⬇

We are pleased to share the presentation from the session, which is available at the following link.